Circulating CD4+CD25hiCD127lo Regulatory T-Cell Levels Do Not Reflect the Extent or Severity of Carotid and Coronary Atherosclerosis

Objective—Regulatory T (Treg) cells play a protective role in experimental atherosclerosis. In the present study, we investigated whether the levels of circulating Treg cells relate to the degree of atherosclerosis in carotid and coronary arteries. Methods and Results—We studied 2 distinct populations: (1) 113 subjects, selected from a free-living population (carotid study), in which we measured the intima-media thickness of the common carotid artery, as a surrogate marker of initial atherosclerosis; and (2) 75 controls and 125 patients with coronary artery disease (coronary study): 36 with chronic stable angina, 50 with non-ST-elevation acute coronary syndrome, 39 with ST-elevation acute myocardial infarction. Treg-cell levels were evaluated by flow cytometry (Treg cells identified as CD3+CD4+CD25highCD127low) and by mRNA expression of forkhead box P3 or of Treg-associated cytokine interleukin 10. In the carotid study, no correlation was observed between Treg-cell levels and intima-media thickness. No differences in Treg-cell levels were observed comparing rapid versus slow intima-media thickness progressors from a subgroup of patients (n=65), in which prospective data on 6-year intima-media thickness progression were available. In the coronary group, Treg-cell levels were not altered in chronic stable angina patients. In contrast, nonunivocal variations were observed in patients suffering an acute coronary syndrome (with a Treg-cell increase in ST-elevation acute myocardial infarction and a Treg-cell decrease in non-ST-elevation acute coronary syndrome patients). Conclusion—The results suggest that determination of circulating Treg-cell levels based on flow cytometry or mRNA assessment is not a useful indicator of the extent or severity of atherosclerosis.

[1]  D. Celermajer,et al.  The "atheroprotective" mediators apolipoprotein A-I and Foxp3 are over-abundant in unstable carotid plaques. , 2010, International journal of cardiology.

[2]  E. Gilboa,et al.  Vaccination against Foxp3(+) regulatory T cells aggravates atherosclerosis. , 2010, Atherosclerosis.

[3]  R. Virmani,et al.  Correlation between carotid intimal/medial thickness and atherosclerosis: a point of view from pathology. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[4]  Gilles Chironi,et al.  The value of carotid intima-media thickness for predicting cardiovascular risk. , 2010, Arteriosclerosis, thrombosis, and vascular biology.

[5]  K. Hirata,et al.  Oral Anti-CD3 Antibody Treatment Induces Regulatory T Cells and Inhibits the Development of Atherosclerosis in Mice , 2009, Circulation.

[6]  G. Norata,et al.  Small dense LDL and VLDL predict common carotid artery IMT and elicit an inflammatory response in peripheral blood mononuclear and endothelial cells. , 2009, Atherosclerosis.

[7]  M. Goldstein,et al.  Blocking angiotensin-converting enzyme induces potent regulatory T cells and modulates TH1- and TH17-mediated autoimmunity , 2009, Proceedings of the National Academy of Sciences.

[8]  H. Björkbacka,et al.  Atheroprotective Effects of Alum Are Associated With Capture of Oxidized LDL Antigens and Activation of Regulatory T Cells , 2009, Circulation research.

[9]  A. Maseri,et al.  Expansion of T-Cell Receptor &zgr;dim Effector T Cells in Acute Coronary Syndromes , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[10]  A. Sharpe,et al.  T-Cell Costimulation and Coinhibition in Atherosclerosis , 2008, Circulation research.

[11]  T. Nomura,et al.  Regulatory T Cells and Immune Tolerance , 2008, Cell.

[12]  C. Garlanda,et al.  Long Pentraxin 3, a Key Component of Innate Immunity, Is Modulated by High-Density Lipoproteins in Endothelial Cells , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[13]  C. Baecher-Allan,et al.  Human regulatory T cells and autoimmunity , 2008, European journal of immunology.

[14]  Yong Chen,et al.  The Th17/Treg imbalance in patients with acute coronary syndrome. , 2008, Clinical immunology.

[15]  G. Keren,et al.  The effect of HMG-CoA reductase inhibitors on naturally occurring CD4+CD25+ T cells. , 2008, Atherosclerosis.

[16]  Lieping Chen,et al.  CD137 Is Expressed in Human Atherosclerosis and Promotes Development of Plaque Inflammation in Hypercholesterolemic Mice , 2008, Circulation.

[17]  P. Teeling,et al.  Low Numbers of FOXP3 Positive Regulatory T Cells Are Present in all Developmental Stages of Human Atherosclerotic Lesions , 2007, PloS one.

[18]  E. Gambineri,et al.  Role of regulatory T cells and FOXP3 in human diseases. , 2007, The Journal of allergy and clinical immunology.

[19]  S. Kaveri,et al.  Atheroprotective effect of CD31 receptor globulin through enrichment of circulating regulatory T-cells. , 2007, Journal of the American College of Cardiology.

[20]  Peng Liu,et al.  The opposite-direction modulation of CD4+CD25+ Tregs and T helper 1 cells in acute coronary syndromes. , 2007, Clinical immunology.

[21]  R. Dahl,et al.  CD4dimCD25bright Treg cell frequencies above a standardized gating threshold are similar in asthmatics and controls , 2007, Cytometry. Part A : the journal of the International Society for Analytical Cytology.

[22]  A. Tedgui,et al.  Regulatory T-cell immunity in atherosclerosis. , 2007, Trends in cardiovascular medicine.

[23]  G. Keren,et al.  Role of Naturally Occurring CD4+CD25+ Regulatory T Cells in Experimental Atherosclerosis , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[24]  F. Neumann,et al.  Cytokine profiles and T cell function in acute coronary syndromes. , 2007, Atherosclerosis.

[25]  J. McCune,et al.  Human CD4+ regulatory T cells express lower levels of the IL-7 receptor alpha chain (CD127), allowing consistent identification and sorting of live cells. , 2007, Journal of immunological methods.

[26]  A. G. Betz,et al.  Alloantigen-enhanced accumulation of CCR5+ ‘effector’ regulatory T cells in the gravid uterus , 2007, Proceedings of the National Academy of Sciences.

[27]  F. Fedele,et al.  Frequency of naturally-occurring regulatory T cells is reduced in patients with ST-segment elevation myocardial infarction. , 2007, Thrombosis research.

[28]  A. Banham.  Cell-surface IL-7 receptor expression facilitates the purification of FOXP3(+) regulatory T cells. , 2006, Trends in immunology.

[29]  G. Keren,et al.  Altered status of CD4(+)CD25(+) regulatory T cells in patients with acute coronary syndromes. , 2006, European heart journal.

[30]  F. Mach,et al.  Short-Term Treatment With Anti-CD3 Antibody Reduces the Development and Progression of Atherosclerosis in Mice , 2006, Circulation.

[31]  W. van Eden,et al.  Induction of Oral Tolerance to Oxidized Low-Density Lipoprotein Ameliorates Atherosclerosis , 2006, Circulation.

[32]  Y. Belkaid,et al.  CCR5-dependent homing of naturally occurring CD4+ regulatory T cells to sites of Leishmania major infection favors pathogen persistence , 2006, The Journal of experimental medicine.

[33]  W. Selby,et al.  Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells , 2006, The Journal of experimental medicine.

[34]  T. Gingeras,et al.  CD127 expression inversely correlates with FoxP3 and suppressive function of human CD4+ T reg cells , 2006, The Journal of experimental medicine.

[35]  Peter Libby,et al.  The immune response in atherosclerosis: a double-edged sword , 2006, Nature Reviews Immunology.

[36]  K. Moore,et al.  Chemokine CXCL10 Promotes Atherogenesis by Modulating the Local Balance of Effector and Regulatory T Cells , 2006, Circulation.

[37]  R. Flavell,et al.  Natural regulatory T cells control the development of atherosclerosis in mice , 2006, Nature Medicine.

[38]  A. Stojadinovic,et al.  Levels of circulating regulatory CD4+CD25+ T cells are decreased in breast cancer patients after vaccination with a HER2/neu peptide (E75) and GM-CSF vaccine★ , 2006, Breast Cancer Research and Treatment.

[39]  J. Serody,et al.  Critical role for CCR5 in the function of donor CD4+CD25+ regulatory T cells during acute graft-versus-host disease. , 2005, Blood.

[40]  P. Isomäki,et al.  CD4+ CD25+ T cells with the phenotypic and functional characteristics of regulatory T cells are enriched in the synovial fluid of patients with rheumatoid arthritis , 2005, Clinical and experimental immunology.

[41]  H. Boehmer,et al.  Mechanisms of suppression by suppressor T cells , 2005, Nature Immunology.

[42]  G. Szot,et al.  Costimulation controls diabetes by altering the balance of pathogenic and regulatory T cells. , 2004, The Journal of clinical investigation.

[43]  A. O’Garra,et al.  Regulatory T cells and mechanisms of immune system control , 2004, Nature Medicine.

[44]  P. Chattopadhyay,et al.  Seventeen-colour flow cytometry: unravelling the immune system , 2004, Nature Reviews Immunology.

[45]  Qingbo Xu,et al.  Heat-Shock Protein 60-Reactive CD4+CD28null T Cells in Patients With Acute Coronary Syndromes , 2004, Circulation.

[46]  J. Piek,et al.  Increased expression of T cell activation markers (CD25, CD26, CD40L and CD69) in atherectomy specimens of patients with unstable angina and acute myocardial infarction. , 2003, Atherosclerosis.

[47]  F. Crea,et al.  Widespread coronary inflammation in unstable angina. , 2003, The New England journal of medicine.

[48]  R. Kronmal,et al.  Carotid-artery intima and media thickness as a risk factor for myocardial infarction and stroke in older adults. Cardiovascular Health Study Collaborative Research Group. , 1999, The New England journal of medicine.

[49]  C. Stewart,et al.  Chapter 4 Multiparameter Analysis of Leukocytes by Flow Cytometry , 1994 .

[50]  C. Stewart,et al.  Multiparameter analysis of leukocytes by flow cytometry. , 1994, Methods in cell biology.

[51]  Stewart Cc.  Multiparameter analysis of leukocytes by flow cytometry. , 1990 .